With respect to the prescription of semaglutide for ensuring weight management, Health Canada has given approval to the 2.4 mg of injection to serve as a measure to be implemented in addition to a reduced calorie diet and increased activity to manage weight in patients having: A BMI of 30 kg/m2 or higher (obesity) A BMI of 27 kg/m2 or higher (overweight) In addition to this, it is also expected that the patient should suffer from chronic weight-related issues, like dyslipidemia, hypertension, or obstructive sleep apnea
Primary outcomes included cataracts, oculomotor binocular dysfunction, visual disturbances, dry eye disease, ametropic accommodative dysfunction, and visual issues with blindness, assessed through Cox proportional hazards models with Bonferroni correction
BMI plays an important role in determining eligibility for GLP-1 weight loss treatments, as it helps assess the degree of obesity and associated health risks
Lab studies show low blood sugar can trigger proteins that make your eye blood vessels leak
If you want structured coaching or accountability, Ivy Rx wont cut it
